Publications by authors named "Mark Feinglos"

Claim this Profile
N
Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept.
Brinnae Bent, Peter J Cho, April Wittmann, Connie Thacker, Srikanth Muppidi, Mark Feinglos

BMJ Open Diabetes Res Care· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering digital biomarkers of interstitial glucose from noninvasive smartwatches.
Brinnae Bent, Peter J Cho, Maria Henriquez, April Wittmann, Connie Thacker, Mark Feinglos

NPJ Digit Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study.
Taehwan Park, Maureen Bresnahan, Scott K Griggs, Jiajing Chen, Alex H Cho, Mark Feinglos

Explor Res Clin Soc Pharm· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open trial of app-assisted acceptance and commitment therapy (iACT) for eating disorders in type 1 diabetes.
Rhonda M Merwin, Ashley A Moskovich, Michael Babyak, Mark Feinglos, Lisa K Honeycutt

J Eat Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Hostility, race, and glucose metabolism in nondiabetic individuals. Diabetes Care 2002;25:835-839.
Richard S Surwit, Redford B Williams, Ilene C Siegler, James D Lane, Michael Helms, Mark N Feinglos

Diabetes Care· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time of Day When Type 1 Diabetes Patients With Eating Disorder Symptoms Most Commonly Restrict Insulin.
Rhonda M Merwin, Ashley A Moskovich, Lisa K Honeycutt, James D Lane, Mark Feinglos

Psychosom Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship of baseline fasting plasma glucose and cardiovascular morbidity and mortality.
Kathryn Evans Kreider, Mark Feinglos

Eur J Intern Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Bress et al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401-1408.
Adam P Bress, Vasilios Papademetriou, Mark N Feinglos

Diabetes Care· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.
Adam P Bress, Jordan B King, Kathryn E Kreider, Srinivasan Beddhu, Debra L Simmons, Mark N Feinglos

Diabetes Care· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer.
Kelli M Luginbuhl, Jeffrey L Schaal, Bret Umstead, Eric M Mastria, Xinghai Li, Mark Feinglos

Nat Biomed Eng· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technosphere insulin: inhaled prandial insulin.
Tracy L Setji, Beatrice D Hong, Mark N Feinglos

Expert Opin Biol Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forty-Year Trends in Tooth Loss Among American Adults With and Without Diabetes Mellitus: An Age-Period-Cohort Analysis.
Huabin Luo, Wei Pan, Frank Sloan, Mark Feinglos, Bei Wu

Prev Chronic Dis· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momentary Predictors of Insulin Restriction Among Adults With Type 1 Diabetes and Eating Disorder Symptomatology.
Rhonda M Merwin, Natalia O Dmitrieva, Lisa K Honeycutt, Ashley A Moskovich, James D Lane, Mark Feinglos

Diabetes Care· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Blood Glucose Self-Monitoring Among Inmates With Diabetes.
Robin N Hunter Buskey, Kathleen Mathieson, Joan S Leafman, Mark N Feinglos

J Correct Health Care· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to care for patients with diabetes in Durham, North Carolina, why are we withholding life-sustaining medications from the patients who need them the most?
Susan E Spratt, Mark N Feinglos, Janese M Willis

Expert Rev Endocrinol Metab· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability.
Susan E Spratt, Bryan C Batch, Lisa P Davis, Ashley A Dunham, Michele Easterling, Mark N Feinglos

J Clin Transl Endocrinol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Education, glucose control, and mortality risks among U.S. older adults with diabetes.
Matthew E Dupre, Mina Silberberg, Janese M Willis, Mark N Feinglos

Diabetes Res Clin Pract· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Bo Ahrén, Susan L Johnson, Murray Stewart, Deborah T Cirkel, Fred Yang, Mark N Feinglos

Diabetes Care· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The how and why of stress, diabetes, and the brain.
Mark Feinglos, Richard Surwit, Stanton R Mehr

Am J Manag Care· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Richard E Pratley, Michael A Nauck, Anthony H Barnett, Mark N Feinglos, Fernando Ovalle

Lancet Diabetes Endocrinol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and preliminary effects of a virtual environment for adults with type 2 diabetes: pilot study.
Constance Johnson, Mark Feinglos, Katherine Pereira, Nancy Hassell, Jim Blascovich

JMIR Res Protoc· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of phenotype definitions for diabetes mellitus.
Rachel L Richesson, Shelley A Rusincovitch, Douglas Wixted, Bryan C Batch, Mark N Feinglos

J Am Med Inform Assoc· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Missing signposts on the roadmap to quality: a call to improve medication adherence indicators in data collection for population research.
Bradi B Granger, Shelley A Rusincovitch, Suzanne Avery, Bryan C Batch, Ashley A Dunham, Mark N Feinglos

Front Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.
Mary Elizabeth Cox, Mark N Feinglos

Curr Diab Rep· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes.
Tracy Setji, Mark Feinglos

Expert Rev Endocrinol Metab· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis